Phathom Pharmaceuticals Inc. PHAT
Super Investor & Insider
Nessuna transazione insider negli ultimi 6 mesi.
Fondi: 13F-HR alla SEC. Insider: acquisti (P) e vendite (S) in borsa da SEC EDGAR, ultimi 12 mesi.
About
Phathom Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases related to acid. Its flagship product, VOQUEZNA (vonoprazan), a potassium-competitive acid blocker, is approved for adults with erosive gastroesophageal reflux disease (GE…
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees371
TickerPHAT
Statistics
Market Cap$871.5M
Revenue (TTM)$175.1M
Net Income-$221.2M
Net Margin-126.3%
EPS$-3.03
P/E-3.47
P/S4.00
P/B-2.56
EV/EBITDA-11.97
ROE50.5%
Dividend Yield—
Price$10.97
Data: Twelve Data · Revenue = mcap / P/S